Texas Attorney General Ken Paxton filed a lawsuit on Tuesday against Johnson & Johnson and Kenvue, the makers of Tylenol, alleging that they concealed information about the drug’s potential connection to autism and ADHD. This legal action follows remarks made by U.S. President Donald Trump, who suggested a link between Tylenol use during pregnancy and autism, a claim lacking scientific evidence.
Johnson & Johnson had been marketing Tylenol for over sixty years before transferring some operations to Kenvue in 2023. Kenvue, which now markets Tylenol, stands by the safety of the product, emphasizing that acetaminophen is the safest pain relief option for pregnant women.
In response to Paxton’s lawsuit, Kenvue stated its intention to defend itself vigorously. Johnson & Johnson refrained from commenting on the lawsuit, asserting that Kenvue is accountable for all aspects of its over-the-counter products, including Tylenol.
Paxton’s complaint, filed in a Texas court, alleges that despite evidence indicating a connection between acetaminophen use during pregnancy and autism/ADHD, Johnson & Johnson and Kenvue failed to warn expectant mothers about associated risks. The Attorney General also accused Johnson & Johnson of violating laws related to deceptive trade practices and fraudulent transfers by spinning off Kenvue.
Kenvue and Johnson & Johnson’s stock prices experienced declines following news of the lawsuit. Paxton cited statements from the Trump administration regarding the risks of using Tylenol during pregnancy and emphasized the need for transparency and accountability in drug marketing.
Health Canada countered Trump’s claims, affirming Tylenol’s safety for treating fever and pain during pregnancy. Despite ongoing legal battles, including lawsuits from families alleging autism and ADHD in children due to prenatal Tylenol exposure, Johnson & Johnson remains entangled in various legal disputes, including a significant number of cancer-related lawsuits.